Loading stock data…
MSB
$28.06+0.27 (+0.97%)
Market ClosedLast close May 1
Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesabi Trust in the Basic Materials sector is trading at $28.06. The stock is currently 34% below its 52-week high of $42.38, remaining 12.2% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why MSB maintains its current current market pressure. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.06
Potential Upside
63.1%
Whystock Fair Value$45.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. The company was incorporated in 1961 and is based in New York, New York.
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$361.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Strong income play. Yield provides a meaningful total return floor.
335.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
81.61%
Volume
Today's trading volume
35,290
Recent News
Assessing Cleveland-Cliffs (CLF) Valuation After Mesabi Trust Distribution Cut Highlights Operational Uncertainty
Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Cleveland-Cliffs (CLF), has drawn fresh attention to uncertainties around the miner’s Northshore iron ore operations and the related industry risks. See our latest analysis for Cleveland-Cliffs. Despite the Mesabi news, Cleveland-Cliffs' recent share price moves have been mixed, with a 1-month share price return of 12.20% and a 90-day share price return showing a 32.45% decline, while the 1-year total...
ASX April 2026 Stocks Estimated To Be Trading Below Fair Value
The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst this fluctuating landscape, identifying stocks that are trading below their fair value can offer potential opportunities for investors looking to capitalize on market inefficiencies.
Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases
Mesoblast Limited ( ASX:MSB ) shareholders (or potential shareholders) will be happy to see that insider Gregory George...
Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?
Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystrophy, enrolling 76 patients aged 5 to 9 with time-to-stand at nine months as the primary endpoint. This trial positions Mesoblast to apply its first-in-class mesenchymal stromal cell therapy, already approved for pediatric steroid-refractory acute graft-versus-host disease, to a new high-need...
Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?
If you are wondering whether Mesoblast at around A$2.02 is still priced attractively or already reflecting high expectations, the valuation story matters more than ever. The share price has seen mixed returns, with a 27.1% decline year to date and a 25.9% gain over the last year, while the three year return of 112.0% contrasts with a 6.6% decline over five years. Recent coverage of Mesoblast has focused on its position within the pharmaceuticals and biotech space and how sentiment around its...